nodes	percent_of_prediction	percent_of_DWPC	metapath
Anagrelide—CYP1A2—Carmustine—hematologic cancer	0.0723	0.146	CbGbCtD
Anagrelide—CYP1A2—Methoxsalen—hematologic cancer	0.0615	0.124	CbGbCtD
Anagrelide—CYP1A2—Bortezomib—hematologic cancer	0.0585	0.118	CbGbCtD
Anagrelide—CYP1A2—Daunorubicin—hematologic cancer	0.056	0.113	CbGbCtD
Anagrelide—CYP1A2—Alitretinoin—hematologic cancer	0.0548	0.11	CbGbCtD
Anagrelide—CYP1A2—Thalidomide—hematologic cancer	0.051	0.103	CbGbCtD
Anagrelide—CYP1A2—Dacarbazine—hematologic cancer	0.0438	0.0882	CbGbCtD
Anagrelide—CYP1A2—Imatinib—hematologic cancer	0.0429	0.0863	CbGbCtD
Anagrelide—CYP1A2—Dasatinib—hematologic cancer	0.0344	0.0693	CbGbCtD
Anagrelide—CYP1A2—Etoposide—hematologic cancer	0.0214	0.0432	CbGbCtD
Anagrelide—PDE3A—hematopoietic system—hematologic cancer	0.000278	0.239	CbGeAlD
Anagrelide—PDE3A—blood—hematologic cancer	0.000184	0.158	CbGeAlD
Anagrelide—PDE3A—lung—hematologic cancer	0.000162	0.139	CbGeAlD
Anagrelide—PDE3A—testis—hematologic cancer	0.000153	0.131	CbGeAlD
Anagrelide—CYP1A2—hematopoietic system—hematologic cancer	0.000123	0.106	CbGeAlD
Anagrelide—PDE3A—lymph node—hematologic cancer	0.000111	0.095	CbGeAlD
Anagrelide—CYP1A2—blood—hematologic cancer	8.17e-05	0.0702	CbGeAlD
Anagrelide—CYP1A2—lung—hematologic cancer	7.16e-05	0.0615	CbGeAlD
Anagrelide—PDE3A—Signaling Pathways—TRIO—hematologic cancer	4.86e-05	0.00143	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—AGO2—hematologic cancer	4.75e-05	0.0014	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—SPHK1—hematologic cancer	4.75e-05	0.0014	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—HDAC9—hematologic cancer	4.7e-05	0.00138	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—LPAR1—hematologic cancer	4.7e-05	0.00138	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—hematologic cancer	4.66e-05	0.00137	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—EP300—hematologic cancer	4.66e-05	0.00137	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—H3F3B—hematologic cancer	4.66e-05	0.00137	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—PIK3CD—hematologic cancer	4.62e-05	0.00136	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—ALB—hematologic cancer	4.56e-05	0.00134	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—hematologic cancer	4.53e-05	0.00133	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—SRC—hematologic cancer	4.53e-05	0.00133	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—GRB2—hematologic cancer	4.49e-05	0.00132	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—CSF2—hematologic cancer	4.42e-05	0.0013	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—hematologic cancer	4.41e-05	0.0013	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—PIK3R1—hematologic cancer	4.36e-05	0.00128	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—hematologic cancer	4.36e-05	0.00128	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PDE4B—hematologic cancer	4.33e-05	0.00127	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CNR2—hematologic cancer	4.33e-05	0.00127	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—FGF19—hematologic cancer	4.29e-05	0.00126	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—PRKCG—hematologic cancer	4.27e-05	0.00126	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—JAK1—hematologic cancer	4.27e-05	0.00126	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—RAC2—hematologic cancer	4.26e-05	0.00125	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—JAK2—hematologic cancer	4.24e-05	0.00125	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—DKK1—hematologic cancer	4.22e-05	0.00124	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—STAT5B—hematologic cancer	4.19e-05	0.00123	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—GBA—hematologic cancer	4.17e-05	0.00123	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ADCY7—hematologic cancer	4.07e-05	0.0012	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—hematologic cancer	4.06e-05	0.00119	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—hematologic cancer	4.05e-05	0.00119	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—PIK3CB—hematologic cancer	4.03e-05	0.00118	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CSF2—hematologic cancer	4.01e-05	0.00118	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—IL2RA—hematologic cancer	3.99e-05	0.00117	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—XIAP—hematologic cancer	3.96e-05	0.00116	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—JAK1—hematologic cancer	3.88e-05	0.00114	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PRKCG—hematologic cancer	3.88e-05	0.00114	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—SH2B3—hematologic cancer	3.86e-05	0.00113	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—SMARCA4—hematologic cancer	3.86e-05	0.00113	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—GZMB—hematologic cancer	3.83e-05	0.00113	CbGpPWpGaD
Anagrelide—Arrhythmia—Epirubicin—hematologic cancer	3.81e-05	8.15e-05	CcSEcCtD
Anagrelide—Pain—Dexamethasone—hematologic cancer	3.81e-05	8.13e-05	CcSEcCtD
Anagrelide—Pain—Betamethasone—hematologic cancer	3.81e-05	8.13e-05	CcSEcCtD
Anagrelide—Visual impairment—Doxorubicin—hematologic cancer	3.81e-05	8.13e-05	CcSEcCtD
Anagrelide—Nervous system disorder—Prednisone—hematologic cancer	3.8e-05	8.12e-05	CcSEcCtD
Anagrelide—Tachycardia—Prednisone—hematologic cancer	3.78e-05	8.08e-05	CcSEcCtD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—hematologic cancer	3.78e-05	0.00111	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—hematologic cancer	3.78e-05	0.00111	CbGpPWpGaD
Anagrelide—Alopecia—Epirubicin—hematologic cancer	3.77e-05	8.06e-05	CcSEcCtD
Anagrelide—Skin disorder—Prednisone—hematologic cancer	3.77e-05	8.05e-05	CcSEcCtD
Anagrelide—CYP1A2—Biological oxidations—GSTP1—hematologic cancer	3.76e-05	0.00111	CbGpPWpGaD
Anagrelide—Nausea—Gemcitabine—hematologic cancer	3.76e-05	8.04e-05	CcSEcCtD
Anagrelide—Vomiting—Cisplatin—hematologic cancer	3.75e-05	8.02e-05	CcSEcCtD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—hematologic cancer	3.75e-05	0.0011	CbGpPWpGaD
Anagrelide—Hyperhidrosis—Prednisone—hematologic cancer	3.75e-05	8.01e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—CTNNA1—hematologic cancer	3.74e-05	0.0011	CbGpPWpGaD
Anagrelide—Vision blurred—Methotrexate—hematologic cancer	3.74e-05	7.99e-05	CcSEcCtD
Anagrelide—Rash—Cisplatin—hematologic cancer	3.72e-05	7.95e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—EIF4EBP1—hematologic cancer	3.72e-05	0.00109	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—HSPB1—hematologic cancer	3.72e-05	0.00109	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CCL3—hematologic cancer	3.72e-05	0.00109	CbGpPWpGaD
Anagrelide—Dermatitis—Cisplatin—hematologic cancer	3.72e-05	7.95e-05	CcSEcCtD
Anagrelide—Malnutrition—Epirubicin—hematologic cancer	3.72e-05	7.94e-05	CcSEcCtD
Anagrelide—CYP1A2—Metapathway biotransformation—GSTP1—hematologic cancer	3.71e-05	0.00109	CbGpPWpGaD
Anagrelide—Diarrhoea—Etoposide—hematologic cancer	3.7e-05	7.91e-05	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—IL2—hematologic cancer	3.7e-05	0.00109	CbGpPWpGaD
Anagrelide—Anorexia—Prednisone—hematologic cancer	3.7e-05	7.9e-05	CcSEcCtD
Anagrelide—Eye disorder—Doxorubicin—hematologic cancer	3.69e-05	7.88e-05	CcSEcCtD
Anagrelide—Ill-defined disorder—Methotrexate—hematologic cancer	3.68e-05	7.87e-05	CcSEcCtD
Anagrelide—Tinnitus—Doxorubicin—hematologic cancer	3.68e-05	7.87e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—SDC1—hematologic cancer	3.68e-05	0.00108	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PTHLH—hematologic cancer	3.68e-05	0.00108	CbGpPWpGaD
Anagrelide—Anaemia—Methotrexate—hematologic cancer	3.67e-05	7.84e-05	CcSEcCtD
Anagrelide—Feeling abnormal—Dexamethasone—hematologic cancer	3.67e-05	7.84e-05	CcSEcCtD
Anagrelide—Feeling abnormal—Betamethasone—hematologic cancer	3.67e-05	7.84e-05	CcSEcCtD
Anagrelide—Cardiac disorder—Doxorubicin—hematologic cancer	3.67e-05	7.83e-05	CcSEcCtD
Anagrelide—Flatulence—Epirubicin—hematologic cancer	3.66e-05	7.82e-05	CcSEcCtD
Anagrelide—Tension—Epirubicin—hematologic cancer	3.65e-05	7.79e-05	CcSEcCtD
Anagrelide—Gastrointestinal pain—Dexamethasone—hematologic cancer	3.64e-05	7.78e-05	CcSEcCtD
Anagrelide—Gastrointestinal pain—Betamethasone—hematologic cancer	3.64e-05	7.78e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—IL2RA—hematologic cancer	3.62e-05	0.00106	CbGpPWpGaD
Anagrelide—Nervousness—Epirubicin—hematologic cancer	3.61e-05	7.71e-05	CcSEcCtD
Anagrelide—Back pain—Epirubicin—hematologic cancer	3.59e-05	7.68e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—PTGER4—hematologic cancer	3.58e-05	0.00105	CbGpPWpGaD
Anagrelide—Malaise—Methotrexate—hematologic cancer	3.58e-05	7.65e-05	CcSEcCtD
Anagrelide—Dizziness—Etoposide—hematologic cancer	3.58e-05	7.64e-05	CcSEcCtD
Anagrelide—Muscle spasms—Epirubicin—hematologic cancer	3.57e-05	7.63e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—LCK—hematologic cancer	3.56e-05	0.00105	CbGpPWpGaD
Anagrelide—Mediastinal disorder—Doxorubicin—hematologic cancer	3.56e-05	7.6e-05	CcSEcCtD
Anagrelide—Chills—Doxorubicin—hematologic cancer	3.54e-05	7.57e-05	CcSEcCtD
Anagrelide—Urticaria—Betamethasone—hematologic cancer	3.54e-05	7.56e-05	CcSEcCtD
Anagrelide—Urticaria—Dexamethasone—hematologic cancer	3.54e-05	7.56e-05	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Prednisone—hematologic cancer	3.53e-05	7.55e-05	CcSEcCtD
Anagrelide—Dizziness—Prednisolone—hematologic cancer	3.53e-05	7.54e-05	CcSEcCtD
Anagrelide—Arrhythmia—Doxorubicin—hematologic cancer	3.53e-05	7.54e-05	CcSEcCtD
Anagrelide—Asthenia—Triamcinolone—hematologic cancer	3.52e-05	7.52e-05	CcSEcCtD
Anagrelide—Body temperature increased—Betamethasone—hematologic cancer	3.52e-05	7.52e-05	CcSEcCtD
Anagrelide—Abdominal pain—Betamethasone—hematologic cancer	3.52e-05	7.52e-05	CcSEcCtD
Anagrelide—Abdominal pain—Dexamethasone—hematologic cancer	3.52e-05	7.52e-05	CcSEcCtD
Anagrelide—Body temperature increased—Dexamethasone—hematologic cancer	3.52e-05	7.52e-05	CcSEcCtD
Anagrelide—Nausea—Cisplatin—hematologic cancer	3.51e-05	7.49e-05	CcSEcCtD
Anagrelide—Insomnia—Prednisone—hematologic cancer	3.51e-05	7.49e-05	CcSEcCtD
Anagrelide—Vision blurred—Epirubicin—hematologic cancer	3.5e-05	7.48e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—H3F3A—hematologic cancer	3.49e-05	0.00103	CbGpPWpGaD
Anagrelide—Alopecia—Doxorubicin—hematologic cancer	3.49e-05	7.46e-05	CcSEcCtD
Anagrelide—Paraesthesia—Prednisone—hematologic cancer	3.48e-05	7.44e-05	CcSEcCtD
Anagrelide—Pruritus—Triamcinolone—hematologic cancer	3.47e-05	7.42e-05	CcSEcCtD
Anagrelide—Cough—Methotrexate—hematologic cancer	3.46e-05	7.4e-05	CcSEcCtD
Anagrelide—CYP1A2—Biological oxidations—GSTM1—hematologic cancer	3.46e-05	0.00102	CbGpPWpGaD
Anagrelide—Ill-defined disorder—Epirubicin—hematologic cancer	3.45e-05	7.37e-05	CcSEcCtD
Anagrelide—Convulsion—Methotrexate—hematologic cancer	3.44e-05	7.35e-05	CcSEcCtD
Anagrelide—Vomiting—Etoposide—hematologic cancer	3.44e-05	7.35e-05	CcSEcCtD
Anagrelide—Malnutrition—Doxorubicin—hematologic cancer	3.44e-05	7.34e-05	CcSEcCtD
Anagrelide—Anaemia—Epirubicin—hematologic cancer	3.43e-05	7.34e-05	CcSEcCtD
Anagrelide—Dyspepsia—Prednisone—hematologic cancer	3.41e-05	7.29e-05	CcSEcCtD
Anagrelide—CYP1A2—Metapathway biotransformation—GSTM1—hematologic cancer	3.41e-05	0.001	CbGpPWpGaD
Anagrelide—Rash—Etoposide—hematologic cancer	3.41e-05	7.29e-05	CcSEcCtD
Anagrelide—Dermatitis—Etoposide—hematologic cancer	3.41e-05	7.28e-05	CcSEcCtD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—FHL2—hematologic cancer	3.4e-05	0.001	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PRKCZ—hematologic cancer	3.4e-05	0.000999	CbGpPWpGaD
Anagrelide—Headache—Etoposide—hematologic cancer	3.39e-05	7.24e-05	CcSEcCtD
Anagrelide—Flatulence—Doxorubicin—hematologic cancer	3.39e-05	7.24e-05	CcSEcCtD
Anagrelide—Myalgia—Methotrexate—hematologic cancer	3.38e-05	7.22e-05	CcSEcCtD
Anagrelide—Arthralgia—Methotrexate—hematologic cancer	3.38e-05	7.22e-05	CcSEcCtD
Anagrelide—Chest pain—Methotrexate—hematologic cancer	3.38e-05	7.22e-05	CcSEcCtD
Anagrelide—Tension—Doxorubicin—hematologic cancer	3.37e-05	7.21e-05	CcSEcCtD
Anagrelide—Decreased appetite—Prednisone—hematologic cancer	3.37e-05	7.2e-05	CcSEcCtD
Anagrelide—Rash—Prednisolone—hematologic cancer	3.36e-05	7.19e-05	CcSEcCtD
Anagrelide—Dermatitis—Prednisolone—hematologic cancer	3.36e-05	7.18e-05	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	3.36e-05	7.17e-05	CcSEcCtD
Anagrelide—Malaise—Epirubicin—hematologic cancer	3.35e-05	7.16e-05	CcSEcCtD
Anagrelide—Fatigue—Prednisone—hematologic cancer	3.34e-05	7.14e-05	CcSEcCtD
Anagrelide—Headache—Prednisolone—hematologic cancer	3.34e-05	7.14e-05	CcSEcCtD
Anagrelide—Discomfort—Methotrexate—hematologic cancer	3.34e-05	7.13e-05	CcSEcCtD
Anagrelide—Nervousness—Doxorubicin—hematologic cancer	3.34e-05	7.13e-05	CcSEcCtD
Anagrelide—Syncope—Epirubicin—hematologic cancer	3.33e-05	7.12e-05	CcSEcCtD
Anagrelide—Back pain—Doxorubicin—hematologic cancer	3.33e-05	7.1e-05	CcSEcCtD
Anagrelide—PDE3A—GPCR downstream signaling—PIK3CG—hematologic cancer	3.32e-05	0.000976	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—EP300—hematologic cancer	3.32e-05	0.000976	CbGpPWpGaD
Anagrelide—Constipation—Prednisone—hematologic cancer	3.32e-05	7.08e-05	CcSEcCtD
Anagrelide—Muscle spasms—Doxorubicin—hematologic cancer	3.31e-05	7.06e-05	CcSEcCtD
Anagrelide—Palpitations—Epirubicin—hematologic cancer	3.28e-05	7.01e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—PARP1—hematologic cancer	3.28e-05	0.000965	CbGpPWpGaD
Anagrelide—Confusional state—Methotrexate—hematologic cancer	3.27e-05	6.98e-05	CcSEcCtD
Anagrelide—Loss of consciousness—Epirubicin—hematologic cancer	3.27e-05	6.98e-05	CcSEcCtD
Anagrelide—Dizziness—Triamcinolone—hematologic cancer	3.24e-05	6.93e-05	CcSEcCtD
Anagrelide—Cough—Epirubicin—hematologic cancer	3.24e-05	6.93e-05	CcSEcCtD
Anagrelide—Vision blurred—Doxorubicin—hematologic cancer	3.24e-05	6.92e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—FBXW7—hematologic cancer	3.23e-05	0.000949	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—SRC—hematologic cancer	3.23e-05	0.000949	CbGpPWpGaD
Anagrelide—Convulsion—Epirubicin—hematologic cancer	3.22e-05	6.88e-05	CcSEcCtD
Anagrelide—Infection—Methotrexate—hematologic cancer	3.22e-05	6.88e-05	CcSEcCtD
Anagrelide—Nausea—Etoposide—hematologic cancer	3.21e-05	6.86e-05	CcSEcCtD
Anagrelide—Hypertension—Epirubicin—hematologic cancer	3.21e-05	6.85e-05	CcSEcCtD
Anagrelide—Feeling abnormal—Prednisone—hematologic cancer	3.2e-05	6.83e-05	CcSEcCtD
Anagrelide—Asthenia—Dexamethasone—hematologic cancer	3.19e-05	6.82e-05	CcSEcCtD
Anagrelide—Asthenia—Betamethasone—hematologic cancer	3.19e-05	6.82e-05	CcSEcCtD
Anagrelide—Ill-defined disorder—Doxorubicin—hematologic cancer	3.19e-05	6.81e-05	CcSEcCtD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—hematologic cancer	3.19e-05	0.000938	CbGpPWpGaD
Anagrelide—Nervous system disorder—Methotrexate—hematologic cancer	3.18e-05	6.79e-05	CcSEcCtD
Anagrelide—Anaemia—Doxorubicin—hematologic cancer	3.18e-05	6.79e-05	CcSEcCtD
Anagrelide—Thrombocytopenia—Methotrexate—hematologic cancer	3.17e-05	6.78e-05	CcSEcCtD
Anagrelide—Gastrointestinal pain—Prednisone—hematologic cancer	3.17e-05	6.77e-05	CcSEcCtD
Anagrelide—Nausea—Prednisolone—hematologic cancer	3.17e-05	6.77e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—HDAC2—hematologic cancer	3.16e-05	0.000931	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CXCR4—hematologic cancer	3.16e-05	0.000931	CbGpPWpGaD
Anagrelide—Myalgia—Epirubicin—hematologic cancer	3.16e-05	6.76e-05	CcSEcCtD
Anagrelide—Arthralgia—Epirubicin—hematologic cancer	3.16e-05	6.76e-05	CcSEcCtD
Anagrelide—Chest pain—Epirubicin—hematologic cancer	3.16e-05	6.76e-05	CcSEcCtD
Anagrelide—Pruritus—Betamethasone—hematologic cancer	3.15e-05	6.73e-05	CcSEcCtD
Anagrelide—Pruritus—Dexamethasone—hematologic cancer	3.15e-05	6.73e-05	CcSEcCtD
Anagrelide—Skin disorder—Methotrexate—hematologic cancer	3.15e-05	6.72e-05	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—VEGFA—hematologic cancer	3.14e-05	0.000924	CbGpPWpGaD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	3.14e-05	6.71e-05	CcSEcCtD
Anagrelide—Hyperhidrosis—Methotrexate—hematologic cancer	3.13e-05	6.69e-05	CcSEcCtD
Anagrelide—Discomfort—Epirubicin—hematologic cancer	3.13e-05	6.68e-05	CcSEcCtD
Anagrelide—Vomiting—Triamcinolone—hematologic cancer	3.12e-05	6.67e-05	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—NRAS—hematologic cancer	3.1e-05	0.000913	CbGpPWpGaD
Anagrelide—Malaise—Doxorubicin—hematologic cancer	3.1e-05	6.62e-05	CcSEcCtD
Anagrelide—Rash—Triamcinolone—hematologic cancer	3.09e-05	6.61e-05	CcSEcCtD
Anagrelide—Dry mouth—Epirubicin—hematologic cancer	3.09e-05	6.61e-05	CcSEcCtD
Anagrelide—Dermatitis—Triamcinolone—hematologic cancer	3.09e-05	6.6e-05	CcSEcCtD
Anagrelide—Anorexia—Methotrexate—hematologic cancer	3.09e-05	6.6e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—CBL—hematologic cancer	3.08e-05	0.000907	CbGpPWpGaD
Anagrelide—Syncope—Doxorubicin—hematologic cancer	3.08e-05	6.59e-05	CcSEcCtD
Anagrelide—Urticaria—Prednisone—hematologic cancer	3.08e-05	6.58e-05	CcSEcCtD
Anagrelide—Headache—Triamcinolone—hematologic cancer	3.07e-05	6.57e-05	CcSEcCtD
Anagrelide—Abdominal pain—Prednisone—hematologic cancer	3.07e-05	6.55e-05	CcSEcCtD
Anagrelide—Body temperature increased—Prednisone—hematologic cancer	3.07e-05	6.55e-05	CcSEcCtD
Anagrelide—Confusional state—Epirubicin—hematologic cancer	3.06e-05	6.53e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—IL3—hematologic cancer	3.05e-05	0.000898	CbGpPWpGaD
Anagrelide—Diarrhoea—Betamethasone—hematologic cancer	3.05e-05	6.51e-05	CcSEcCtD
Anagrelide—Diarrhoea—Dexamethasone—hematologic cancer	3.05e-05	6.51e-05	CcSEcCtD
Anagrelide—Palpitations—Doxorubicin—hematologic cancer	3.04e-05	6.49e-05	CcSEcCtD
Anagrelide—Oedema—Epirubicin—hematologic cancer	3.03e-05	6.48e-05	CcSEcCtD
Anagrelide—Hypotension—Methotrexate—hematologic cancer	3.03e-05	6.47e-05	CcSEcCtD
Anagrelide—Loss of consciousness—Doxorubicin—hematologic cancer	3.02e-05	6.46e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—PIK3CG—hematologic cancer	3.01e-05	0.000887	CbGpPWpGaD
Anagrelide—Infection—Epirubicin—hematologic cancer	3.01e-05	6.44e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—PTPN1—hematologic cancer	3e-05	0.000882	CbGpPWpGaD
Anagrelide—Cough—Doxorubicin—hematologic cancer	3e-05	6.41e-05	CcSEcCtD
Anagrelide—Shock—Epirubicin—hematologic cancer	2.98e-05	6.37e-05	CcSEcCtD
Anagrelide—Convulsion—Doxorubicin—hematologic cancer	2.98e-05	6.36e-05	CcSEcCtD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ARNTL—hematologic cancer	2.97e-05	0.000875	CbGpPWpGaD
Anagrelide—Nervous system disorder—Epirubicin—hematologic cancer	2.97e-05	6.35e-05	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—MAPK3—hematologic cancer	2.97e-05	0.000874	CbGpPWpGaD
Anagrelide—Thrombocytopenia—Epirubicin—hematologic cancer	2.97e-05	6.34e-05	CcSEcCtD
Anagrelide—Hypertension—Doxorubicin—hematologic cancer	2.97e-05	6.34e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—PTPN11—hematologic cancer	2.96e-05	0.000871	CbGpPWpGaD
Anagrelide—Tachycardia—Epirubicin—hematologic cancer	2.96e-05	6.32e-05	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Methotrexate—hematologic cancer	2.95e-05	6.31e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—RASGRP1—hematologic cancer	2.95e-05	0.000868	CbGpPWpGaD
Anagrelide—Skin disorder—Epirubicin—hematologic cancer	2.95e-05	6.29e-05	CcSEcCtD
Anagrelide—Dizziness—Dexamethasone—hematologic cancer	2.94e-05	6.29e-05	CcSEcCtD
Anagrelide—Dizziness—Betamethasone—hematologic cancer	2.94e-05	6.29e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—SYK—hematologic cancer	2.94e-05	0.000865	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—HSP90AA1—hematologic cancer	2.94e-05	0.000865	CbGpPWpGaD
Anagrelide—Hyperhidrosis—Epirubicin—hematologic cancer	2.93e-05	6.26e-05	CcSEcCtD
Anagrelide—Insomnia—Methotrexate—hematologic cancer	2.93e-05	6.26e-05	CcSEcCtD
Anagrelide—Myalgia—Doxorubicin—hematologic cancer	2.93e-05	6.25e-05	CcSEcCtD
Anagrelide—Arthralgia—Doxorubicin—hematologic cancer	2.93e-05	6.25e-05	CcSEcCtD
Anagrelide—Chest pain—Doxorubicin—hematologic cancer	2.93e-05	6.25e-05	CcSEcCtD
Anagrelide—PDE3A—GPCR downstream signaling—PIK3CD—hematologic cancer	2.92e-05	0.000858	CbGpPWpGaD
Anagrelide—Nausea—Triamcinolone—hematologic cancer	2.91e-05	6.23e-05	CcSEcCtD
Anagrelide—Paraesthesia—Methotrexate—hematologic cancer	2.91e-05	6.22e-05	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	2.91e-05	6.21e-05	CcSEcCtD
Anagrelide—Discomfort—Doxorubicin—hematologic cancer	2.89e-05	6.18e-05	CcSEcCtD
Anagrelide—Anorexia—Epirubicin—hematologic cancer	2.89e-05	6.18e-05	CcSEcCtD
Anagrelide—Dyspnoea—Methotrexate—hematologic cancer	2.89e-05	6.17e-05	CcSEcCtD
Anagrelide—CYP1A2—Metabolism—GMPS—hematologic cancer	2.89e-05	0.000849	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—FTCD—hematologic cancer	2.89e-05	0.000849	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PHYH—hematologic cancer	2.89e-05	0.000849	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—TGFB1—hematologic cancer	2.88e-05	0.000848	CbGpPWpGaD
Anagrelide—Somnolence—Methotrexate—hematologic cancer	2.88e-05	6.15e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—CREB1—hematologic cancer	2.87e-05	0.000844	CbGpPWpGaD
Anagrelide—Dry mouth—Doxorubicin—hematologic cancer	2.86e-05	6.12e-05	CcSEcCtD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—NCOR2—hematologic cancer	2.86e-05	0.00084	CbGpPWpGaD
Anagrelide—Dyspepsia—Methotrexate—hematologic cancer	2.85e-05	6.09e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—STAT1—hematologic cancer	2.84e-05	0.000834	CbGpPWpGaD
Anagrelide—Hypotension—Epirubicin—hematologic cancer	2.83e-05	6.05e-05	CcSEcCtD
Anagrelide—Vomiting—Dexamethasone—hematologic cancer	2.83e-05	6.05e-05	CcSEcCtD
Anagrelide—Vomiting—Betamethasone—hematologic cancer	2.83e-05	6.05e-05	CcSEcCtD
Anagrelide—Confusional state—Doxorubicin—hematologic cancer	2.83e-05	6.04e-05	CcSEcCtD
Anagrelide—Decreased appetite—Methotrexate—hematologic cancer	2.82e-05	6.02e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—CCL2—hematologic cancer	2.81e-05	0.000826	CbGpPWpGaD
Anagrelide—Rash—Betamethasone—hematologic cancer	2.81e-05	6e-05	CcSEcCtD
Anagrelide—Rash—Dexamethasone—hematologic cancer	2.81e-05	6e-05	CcSEcCtD
Anagrelide—Oedema—Doxorubicin—hematologic cancer	2.81e-05	5.99e-05	CcSEcCtD
Anagrelide—Dermatitis—Betamethasone—hematologic cancer	2.8e-05	5.99e-05	CcSEcCtD
Anagrelide—Dermatitis—Dexamethasone—hematologic cancer	2.8e-05	5.99e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—IL6R—hematologic cancer	2.8e-05	0.000823	CbGpPWpGaD
Anagrelide—Gastrointestinal disorder—Methotrexate—hematologic cancer	2.8e-05	5.98e-05	CcSEcCtD
Anagrelide—Fatigue—Methotrexate—hematologic cancer	2.79e-05	5.97e-05	CcSEcCtD
Anagrelide—Headache—Dexamethasone—hematologic cancer	2.79e-05	5.96e-05	CcSEcCtD
Anagrelide—Headache—Betamethasone—hematologic cancer	2.79e-05	5.96e-05	CcSEcCtD
Anagrelide—Infection—Doxorubicin—hematologic cancer	2.79e-05	5.96e-05	CcSEcCtD
Anagrelide—Asthenia—Prednisone—hematologic cancer	2.78e-05	5.94e-05	CcSEcCtD
Anagrelide—Pain—Methotrexate—hematologic cancer	2.77e-05	5.92e-05	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Epirubicin—hematologic cancer	2.76e-05	5.9e-05	CcSEcCtD
Anagrelide—Shock—Doxorubicin—hematologic cancer	2.76e-05	5.9e-05	CcSEcCtD
Anagrelide—PDE3A—GPCR downstream signaling—PIK3R1—hematologic cancer	2.76e-05	0.000811	CbGpPWpGaD
Anagrelide—Nervous system disorder—Doxorubicin—hematologic cancer	2.75e-05	5.88e-05	CcSEcCtD
Anagrelide—Thrombocytopenia—Doxorubicin—hematologic cancer	2.75e-05	5.87e-05	CcSEcCtD
Anagrelide—Pruritus—Prednisone—hematologic cancer	2.74e-05	5.86e-05	CcSEcCtD
Anagrelide—Insomnia—Epirubicin—hematologic cancer	2.74e-05	5.86e-05	CcSEcCtD
Anagrelide—Tachycardia—Doxorubicin—hematologic cancer	2.74e-05	5.85e-05	CcSEcCtD
Anagrelide—Skin disorder—Doxorubicin—hematologic cancer	2.73e-05	5.82e-05	CcSEcCtD
Anagrelide—Paraesthesia—Epirubicin—hematologic cancer	2.72e-05	5.82e-05	CcSEcCtD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—IDH1—hematologic cancer	2.72e-05	0.0008	CbGpPWpGaD
Anagrelide—Hyperhidrosis—Doxorubicin—hematologic cancer	2.71e-05	5.79e-05	CcSEcCtD
Anagrelide—Dyspnoea—Epirubicin—hematologic cancer	2.7e-05	5.78e-05	CcSEcCtD
Anagrelide—Somnolence—Epirubicin—hematologic cancer	2.7e-05	5.76e-05	CcSEcCtD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ABCC3—hematologic cancer	2.69e-05	0.000791	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—JAK2—hematologic cancer	2.68e-05	0.000788	CbGpPWpGaD
Anagrelide—Anorexia—Doxorubicin—hematologic cancer	2.67e-05	5.71e-05	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—KRAS—hematologic cancer	2.67e-05	0.000786	CbGpPWpGaD
Anagrelide—Feeling abnormal—Methotrexate—hematologic cancer	2.67e-05	5.7e-05	CcSEcCtD
Anagrelide—Dyspepsia—Epirubicin—hematologic cancer	2.67e-05	5.7e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—MAP2K1—hematologic cancer	2.67e-05	0.000785	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—GRB2—hematologic cancer	2.65e-05	0.000781	CbGpPWpGaD
Anagrelide—Diarrhoea—Prednisone—hematologic cancer	2.65e-05	5.67e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—PIK3CD—hematologic cancer	2.65e-05	0.00078	CbGpPWpGaD
Anagrelide—Gastrointestinal pain—Methotrexate—hematologic cancer	2.65e-05	5.66e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—PDGFA—hematologic cancer	2.65e-05	0.000779	CbGpPWpGaD
Anagrelide—Nausea—Dexamethasone—hematologic cancer	2.64e-05	5.65e-05	CcSEcCtD
Anagrelide—Nausea—Betamethasone—hematologic cancer	2.64e-05	5.65e-05	CcSEcCtD
Anagrelide—CYP1A2—Metabolism—SMPD3—hematologic cancer	2.64e-05	0.000776	CbGpPWpGaD
Anagrelide—Decreased appetite—Epirubicin—hematologic cancer	2.64e-05	5.63e-05	CcSEcCtD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—SPHK1—hematologic cancer	2.63e-05	0.000774	CbGpPWpGaD
Anagrelide—Hypotension—Doxorubicin—hematologic cancer	2.62e-05	5.6e-05	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Epirubicin—hematologic cancer	2.62e-05	5.59e-05	CcSEcCtD
Anagrelide—Fatigue—Epirubicin—hematologic cancer	2.61e-05	5.59e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—KITLG—hematologic cancer	2.61e-05	0.000768	CbGpPWpGaD
Anagrelide—Constipation—Epirubicin—hematologic cancer	2.59e-05	5.54e-05	CcSEcCtD
Anagrelide—Pain—Epirubicin—hematologic cancer	2.59e-05	5.54e-05	CcSEcCtD
Anagrelide—Urticaria—Methotrexate—hematologic cancer	2.57e-05	5.5e-05	CcSEcCtD
Anagrelide—Dizziness—Prednisone—hematologic cancer	2.56e-05	5.48e-05	CcSEcCtD
Anagrelide—Body temperature increased—Methotrexate—hematologic cancer	2.56e-05	5.47e-05	CcSEcCtD
Anagrelide—Abdominal pain—Methotrexate—hematologic cancer	2.56e-05	5.47e-05	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	2.56e-05	5.46e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—STAT5A—hematologic cancer	2.55e-05	0.00075	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—PIK3CB—hematologic cancer	2.54e-05	0.000748	CbGpPWpGaD
Anagrelide—Insomnia—Doxorubicin—hematologic cancer	2.54e-05	5.42e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—CDKN2B—hematologic cancer	2.53e-05	0.000744	CbGpPWpGaD
Anagrelide—Paraesthesia—Doxorubicin—hematologic cancer	2.52e-05	5.38e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—PIK3R1—hematologic cancer	2.5e-05	0.000736	CbGpPWpGaD
Anagrelide—Dyspnoea—Doxorubicin—hematologic cancer	2.5e-05	5.34e-05	CcSEcCtD
Anagrelide—Feeling abnormal—Epirubicin—hematologic cancer	2.5e-05	5.34e-05	CcSEcCtD
Anagrelide—Somnolence—Doxorubicin—hematologic cancer	2.49e-05	5.33e-05	CcSEcCtD
Anagrelide—Gastrointestinal pain—Epirubicin—hematologic cancer	2.48e-05	5.3e-05	CcSEcCtD
Anagrelide—Dyspepsia—Doxorubicin—hematologic cancer	2.47e-05	5.28e-05	CcSEcCtD
Anagrelide—Vomiting—Prednisone—hematologic cancer	2.47e-05	5.27e-05	CcSEcCtD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—hematologic cancer	2.46e-05	0.000724	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—PIK3CA—hematologic cancer	2.45e-05	0.000722	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CD86—hematologic cancer	2.45e-05	0.000719	CbGpPWpGaD
Anagrelide—Rash—Prednisone—hematologic cancer	2.44e-05	5.22e-05	CcSEcCtD
Anagrelide—Dermatitis—Prednisone—hematologic cancer	2.44e-05	5.22e-05	CcSEcCtD
Anagrelide—Decreased appetite—Doxorubicin—hematologic cancer	2.44e-05	5.21e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—JAK2—hematologic cancer	2.43e-05	0.000715	CbGpPWpGaD
Anagrelide—Headache—Prednisone—hematologic cancer	2.43e-05	5.19e-05	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Doxorubicin—hematologic cancer	2.42e-05	5.18e-05	CcSEcCtD
Anagrelide—Fatigue—Doxorubicin—hematologic cancer	2.42e-05	5.17e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—HES1—hematologic cancer	2.41e-05	0.00071	CbGpPWpGaD
Anagrelide—Urticaria—Epirubicin—hematologic cancer	2.41e-05	5.15e-05	CcSEcCtD
Anagrelide—Pain—Doxorubicin—hematologic cancer	2.4e-05	5.13e-05	CcSEcCtD
Anagrelide—Constipation—Doxorubicin—hematologic cancer	2.4e-05	5.13e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—NCOR1—hematologic cancer	2.4e-05	0.000705	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ALOX5—hematologic cancer	2.4e-05	0.000705	CbGpPWpGaD
Anagrelide—Body temperature increased—Epirubicin—hematologic cancer	2.4e-05	5.12e-05	CcSEcCtD
Anagrelide—Abdominal pain—Epirubicin—hematologic cancer	2.4e-05	5.12e-05	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—TP53—hematologic cancer	2.37e-05	0.000698	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CSF2—hematologic cancer	2.37e-05	0.000698	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—FGF1—hematologic cancer	2.37e-05	0.000698	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—FOXO1—hematologic cancer	2.34e-05	0.000687	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—IL2—hematologic cancer	2.34e-05	0.000687	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PDGFRB—hematologic cancer	2.33e-05	0.000686	CbGpPWpGaD
Anagrelide—Asthenia—Methotrexate—hematologic cancer	2.32e-05	4.97e-05	CcSEcCtD
Anagrelide—Feeling abnormal—Doxorubicin—hematologic cancer	2.31e-05	4.94e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—PIK3CB—hematologic cancer	2.31e-05	0.000679	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—B3GAT1—hematologic cancer	2.31e-05	0.000678	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ASNS—hematologic cancer	2.31e-05	0.000678	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—DCK—hematologic cancer	2.31e-05	0.000678	CbGpPWpGaD
Anagrelide—Nausea—Prednisone—hematologic cancer	2.3e-05	4.92e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—PDGFRA—hematologic cancer	2.3e-05	0.000676	CbGpPWpGaD
Anagrelide—Gastrointestinal pain—Doxorubicin—hematologic cancer	2.29e-05	4.9e-05	CcSEcCtD
Anagrelide—Pruritus—Methotrexate—hematologic cancer	2.29e-05	4.9e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—JAK1—hematologic cancer	2.29e-05	0.000673	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PRKCG—hematologic cancer	2.29e-05	0.000673	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—HRAS—hematologic cancer	2.27e-05	0.000668	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—NCOA3—hematologic cancer	2.25e-05	0.000663	CbGpPWpGaD
Anagrelide—Urticaria—Doxorubicin—hematologic cancer	2.23e-05	4.76e-05	CcSEcCtD
Anagrelide—Body temperature increased—Doxorubicin—hematologic cancer	2.22e-05	4.74e-05	CcSEcCtD
Anagrelide—Abdominal pain—Doxorubicin—hematologic cancer	2.22e-05	4.74e-05	CcSEcCtD
Anagrelide—Diarrhoea—Methotrexate—hematologic cancer	2.22e-05	4.74e-05	CcSEcCtD
Anagrelide—CYP1A2—Metabolism—HDC—hematologic cancer	2.19e-05	0.000643	CbGpPWpGaD
Anagrelide—Asthenia—Epirubicin—hematologic cancer	2.18e-05	4.65e-05	CcSEcCtD
Anagrelide—Pruritus—Epirubicin—hematologic cancer	2.15e-05	4.58e-05	CcSEcCtD
Anagrelide—Dizziness—Methotrexate—hematologic cancer	2.14e-05	4.58e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—IL2RA—hematologic cancer	2.14e-05	0.000629	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—IL2—hematologic cancer	2.12e-05	0.000624	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TERT—hematologic cancer	2.11e-05	0.000622	CbGpPWpGaD
Anagrelide—Diarrhoea—Epirubicin—hematologic cancer	2.07e-05	4.43e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—PDGFB—hematologic cancer	2.06e-05	0.000607	CbGpPWpGaD
Anagrelide—Vomiting—Methotrexate—hematologic cancer	2.06e-05	4.4e-05	CcSEcCtD
Anagrelide—Rash—Methotrexate—hematologic cancer	2.04e-05	4.36e-05	CcSEcCtD
Anagrelide—Dermatitis—Methotrexate—hematologic cancer	2.04e-05	4.36e-05	CcSEcCtD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—SDC1—hematologic cancer	2.04e-05	0.0006	CbGpPWpGaD
Anagrelide—Headache—Methotrexate—hematologic cancer	2.03e-05	4.34e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—TSC2—hematologic cancer	2.02e-05	0.000593	CbGpPWpGaD
Anagrelide—Asthenia—Doxorubicin—hematologic cancer	2.01e-05	4.3e-05	CcSEcCtD
Anagrelide—Dizziness—Epirubicin—hematologic cancer	2.01e-05	4.28e-05	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—AKT1—hematologic cancer	2e-05	0.00059	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CDA—hematologic cancer	2e-05	0.000588	CbGpPWpGaD
Anagrelide—Pruritus—Doxorubicin—hematologic cancer	1.99e-05	4.24e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—FGFR3—hematologic cancer	1.94e-05	0.000571	CbGpPWpGaD
Anagrelide—Vomiting—Epirubicin—hematologic cancer	1.93e-05	4.12e-05	CcSEcCtD
Anagrelide—CYP1A2—Metabolism—PC—hematologic cancer	1.92e-05	0.000566	CbGpPWpGaD
Anagrelide—Nausea—Methotrexate—hematologic cancer	1.92e-05	4.11e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—MAPK14—hematologic cancer	1.92e-05	0.000565	CbGpPWpGaD
Anagrelide—Diarrhoea—Doxorubicin—hematologic cancer	1.92e-05	4.1e-05	CcSEcCtD
Anagrelide—Rash—Epirubicin—hematologic cancer	1.91e-05	4.08e-05	CcSEcCtD
Anagrelide—Dermatitis—Epirubicin—hematologic cancer	1.91e-05	4.08e-05	CcSEcCtD
Anagrelide—Headache—Epirubicin—hematologic cancer	1.9e-05	4.06e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—ESR1—hematologic cancer	1.88e-05	0.000554	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—FN1—hematologic cancer	1.86e-05	0.000547	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GBA—hematologic cancer	1.86e-05	0.000547	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SLC35B2—hematologic cancer	1.86e-05	0.000547	CbGpPWpGaD
Anagrelide—Dizziness—Doxorubicin—hematologic cancer	1.86e-05	3.96e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—NFKBIA—hematologic cancer	1.84e-05	0.000541	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—BAD—hematologic cancer	1.84e-05	0.000541	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NOTCH1—hematologic cancer	1.82e-05	0.000536	CbGpPWpGaD
Anagrelide—Nausea—Epirubicin—hematologic cancer	1.8e-05	3.85e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—CD80—hematologic cancer	1.78e-05	0.000525	CbGpPWpGaD
Anagrelide—Vomiting—Doxorubicin—hematologic cancer	1.78e-05	3.81e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—KIT—hematologic cancer	1.78e-05	0.000524	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PIK3CG—hematologic cancer	1.78e-05	0.000524	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—NRAS—hematologic cancer	1.78e-05	0.000524	CbGpPWpGaD
Anagrelide—Rash—Doxorubicin—hematologic cancer	1.77e-05	3.78e-05	CcSEcCtD
Anagrelide—Dermatitis—Doxorubicin—hematologic cancer	1.77e-05	3.78e-05	CcSEcCtD
Anagrelide—Headache—Doxorubicin—hematologic cancer	1.76e-05	3.76e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—PTPN11—hematologic cancer	1.75e-05	0.000515	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—MAPK3—hematologic cancer	1.71e-05	0.000502	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—MTAP—hematologic cancer	1.7e-05	0.0005	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CREB1—hematologic cancer	1.7e-05	0.000499	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—BRAF—hematologic cancer	1.67e-05	0.000492	CbGpPWpGaD
Anagrelide—Nausea—Doxorubicin—hematologic cancer	1.67e-05	3.56e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—CCL2—hematologic cancer	1.66e-05	0.000488	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IL6R—hematologic cancer	1.65e-05	0.000486	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CREBBP—hematologic cancer	1.65e-05	0.000486	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MAP2K1—hematologic cancer	1.58e-05	0.000464	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PIK3CD—hematologic cancer	1.57e-05	0.00046	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—PIK3CA—hematologic cancer	1.55e-05	0.000456	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—KRAS—hematologic cancer	1.53e-05	0.000451	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—FHL2—hematologic cancer	1.52e-05	0.000446	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—FGF2—hematologic cancer	1.5e-05	0.000441	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—AGRN—hematologic cancer	1.49e-05	0.000437	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PIK3R1—hematologic cancer	1.48e-05	0.000435	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—JAK2—hematologic cancer	1.44e-05	0.000423	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—IDH2—hematologic cancer	1.41e-05	0.000414	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HMMR—hematologic cancer	1.41e-05	0.000414	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PIK3CA—hematologic cancer	1.41e-05	0.000414	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MDM2—hematologic cancer	1.4e-05	0.000413	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MTOR—hematologic cancer	1.36e-05	0.000401	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PIK3CB—hematologic cancer	1.36e-05	0.000401	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—hematologic cancer	1.33e-05	0.000391	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ARNTL—hematologic cancer	1.32e-05	0.00039	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—HRAS—hematologic cancer	1.3e-05	0.000383	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CA9—hematologic cancer	1.29e-05	0.000379	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ACP5—hematologic cancer	1.29e-05	0.000379	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CDKN1B—hematologic cancer	1.28e-05	0.000377	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—NCOR2—hematologic cancer	1.27e-05	0.000374	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—AKT1—hematologic cancer	1.27e-05	0.000373	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CASP3—hematologic cancer	1.26e-05	0.000369	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IL2—hematologic cancer	1.25e-05	0.000369	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—IL6—hematologic cancer	1.25e-05	0.000367	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CCND1—hematologic cancer	1.22e-05	0.000359	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—JUN—hematologic cancer	1.22e-05	0.000359	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—IDH1—hematologic cancer	1.21e-05	0.000356	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—TXN—hematologic cancer	1.2e-05	0.000352	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ABCC3—hematologic cancer	1.2e-05	0.000352	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTO1—hematologic cancer	1.2e-05	0.000352	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CDKN1A—hematologic cancer	1.18e-05	0.000348	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PTEN—hematologic cancer	1.18e-05	0.000347	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SPHK1—hematologic cancer	1.17e-05	0.000345	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MAPK8—hematologic cancer	1.15e-05	0.000339	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—AKT1—hematologic cancer	1.15e-05	0.000338	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—UGT1A1—hematologic cancer	1.13e-05	0.000331	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—EP300—hematologic cancer	1.12e-05	0.000331	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CRABP1—hematologic cancer	1.1e-05	0.000322	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SLC22A1—hematologic cancer	1.1e-05	0.000322	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—SRC—hematologic cancer	1.09e-05	0.000322	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALOX5—hematologic cancer	1.07e-05	0.000314	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—VEGFA—hematologic cancer	1.07e-05	0.000313	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—STAT3—hematologic cancer	1.05e-05	0.00031	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NRAS—hematologic cancer	1.05e-05	0.000309	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—NUP98—hematologic cancer	1.03e-05	0.000304	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MAPK3—hematologic cancer	1.01e-05	0.000296	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ADCY7—hematologic cancer	1e-05	0.000295	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—NCOA3—hematologic cancer	1e-05	0.000295	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—NUP214—hematologic cancer	9.97e-06	0.000293	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	9.87e-06	0.00029	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MYC—hematologic cancer	9.8e-06	0.000288	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TGFB1—hematologic cancer	9.78e-06	0.000288	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ABCG2—hematologic cancer	9.77e-06	0.000287	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—MTR—hematologic cancer	9.77e-06	0.000287	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ENO2—hematologic cancer	9.58e-06	0.000282	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTT1—hematologic cancer	9.29e-06	0.000273	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	9.15e-06	0.000269	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SDC1—hematologic cancer	9.08e-06	0.000267	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—KRAS—hematologic cancer	9.06e-06	0.000266	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	8.67e-06	0.000255	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	8.56e-06	0.000252	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PIK3CA—hematologic cancer	8.32e-06	0.000245	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	8.19e-06	0.000241	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TP53—hematologic cancer	8.05e-06	0.000237	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CD44—hematologic cancer	7.72e-06	0.000227	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—NQO1—hematologic cancer	7.72e-06	0.000227	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—HRAS—hematologic cancer	7.7e-06	0.000226	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	7.56e-06	0.000222	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IL6—hematologic cancer	7.37e-06	0.000217	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYCS—hematologic cancer	7.3e-06	0.000215	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HSP90AA1—hematologic cancer	7.26e-06	0.000213	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—AKT1—hematologic cancer	6.8e-06	0.0002	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	6.53e-06	0.000192	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTP1—hematologic cancer	6.44e-06	0.000189	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	6.23e-06	0.000183	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ABCB1—hematologic cancer	6.09e-06	0.000179	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTM1—hematologic cancer	5.92e-06	0.000174	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—NCOR1—hematologic cancer	5.92e-06	0.000174	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—MTHFR—hematologic cancer	5.23e-06	0.000154	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	4.61e-06	0.000136	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PIK3CG—hematologic cancer	4.39e-06	0.000129	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CREBBP—hematologic cancer	4.07e-06	0.00012	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PIK3CD—hematologic cancer	3.86e-06	0.000114	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALB—hematologic cancer	3.81e-06	0.000112	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PIK3R1—hematologic cancer	3.65e-06	0.000107	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PIK3CB—hematologic cancer	3.37e-06	9.9e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PTEN—hematologic cancer	2.91e-06	8.56e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—EP300—hematologic cancer	2.77e-06	8.16e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PIK3CA—hematologic cancer	2.05e-06	6.04e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—AKT1—hematologic cancer	1.68e-06	4.93e-05	CbGpPWpGaD
